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couple of different scenarios of smoking initiation. Birth and death rates of the 
general population are assumed to be the average of the previous decade. Relative 
Risk of mortality is assumed to be the same. Results: Smoking prevalence in 
2024 is estimated to be 18.5%, even with alternate hypotheses around smoking 
initiation in the 2012-2022 decade. ConClusions: Aging of smoker population 
will continue to contribute to reducing prevalence of smokers. Existing dynamic 
forecasting models were re-created and used to estimate smoker prevalence using 
recent data.
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objeCtives: In Sweden, reimbursement for roflumilast is limited to eligible patients 
with severe to very severe chronic obstructive pulmonary disease (COPD) who are 
intolerant to inhaled corticosteroid therapy. Therefore, patients being treated 
with roflumilast in Sweden may differ by their characteristics to patients in other 
countries. Our aim was to describe demographic and disease characteristics of 
patients with COPD prescribed roflumilast in Sweden, at time of first prescrip-
tion. Methods: Patients with diagnoses of COPD or chronic bronchitis (CB) who 
initiated use of roflumilast at age ≥ 40 during 2011 were identified from the Swedish 
Hospital Discharge Register and Swedish Prescribed Drug Register. Summary sta-
tistics were calculated for demographic and disease characteristics at time of first 
prescription. The Charlson comorbidity index (CCI) was used to score the pres-
ence of comorbidities. Results: 1,161 patients (42.8% male) with COPD/CB initi-
ated roflumilast. Mean age at time of first prescription was 70.8 (SD±8.3) years. 
Mean time since first COPD diagnosis was 6.1 (SD±3.8) years. 640 (55.1%) patients 
were hospitalized at least once in the year prior; 99 (8.5%) had ≥ 5 hospitalisations 
in this period. 21.7% of patients had congestive heart failure, 13.5% myocardial 
infarction, 17.1% diabetes, and 9.1% a mood disorder indicated in their medical 
records. 37.2% of patients had a CCI score ≥ 3 at time of first roflumilast prescrip-
tion. ConClusions: Patients who are prescribed roflumilast carry a very severe 
disease burden. Appropriate methodology should be used when making compari-
sons between patients who are exposed to roflumilast to those who are not, using 
real world data in Sweden.
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Widespread evidence has demonstrated the negative effects of tobacco smoking 
in patients with diabetes. Although many studies have explored the prevalence of 
tobacco smoking in the general population, data are lacking regarding its preva-
lence in a specific population with a chronic disease such as diabetes.objeCtives: 
This study aims to determine the prevalence of tobacco smoking among patients 
with diabetes in Hospital Pulau Pinang, Malaysia. Methods: A cross-sectional 
survey was conducted to study diabetic patients who attended the endocrine 
clinic at Hospital Pulau Pinang in Malaysia from March to August 2012. All the 
diabetic patients who attended the endocrine clinic during that period were 
asked about their smoking status, and their medical records were reviewed. A 
total of 1,118 patients with diabetes were reviewed to determine the prevalence 
of tobacco smoking in diabetic patients at the endocrine clinic of Hospital Pulau 
Pinang. Results: The majority of the study population was male, with Malay 
and Chinese patients in almost equal proportions and a smaller proportion of 
Indian patients. Most of these patients had started smoking before they were diag-
nosed with diabetes. Among the 1,118 diabetic patients, only 108 patients smoked; 
therefore, the prevalence of tobacco smoking in our patients with diabetes was 
9.66%. ConClusions: A low prevalence of tobacco smoking was estimated in 
this study. This prevalence is close to the corresponding value in the general 
population in Malaysia.
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a progressive con-
dition which is characterized by a dramatic socio-economic impact. Sensitivity of 
clinical signs and lung function in predicting death is variable in different COPD 
phenotypes. AiM: To assess the predictive value of COPD annual cost on mortal-
ity. Methods: Gender; age; smoking habit, clinical data, and complete lung fun-
tion were assessed in 275 consecutive COPD patients aged > 40y together with the 
annual cost calculated over the last twelve months. stAtistiCs: t test for com-
paring means ± sd; linear regression for checking any relationship between each 
variable and mortality (p< 0.05 was accepted). Results: The whole mortality was 
40.4% over three years (n= 12; 47, and 52 subjects, respectively). Subjects still sur-
vived after three years (n= 164) proved originally different from those (n= 111) who 
died in terms of mean age; FEV1 (in l); RV; TLCO/VA; 6’ walking test; BODE index, and 
Charlson index (all p< 0.001), but not of FEV1% pred. and FEV1/FVC (p= ns). Mean total 
(29.0%), venom 31 (8.0%), drug 28 (7.2%), other/unknown 217 (55.8%). The prescrip-
tion rate of self-injection epinephrine immediately after the anaphylaxis was 10.9% 
(after the insurance started to cover the service in 2011/9). ConClusions: This 
is the first report on the incidence of anaphylaxis in general population in Japan; 
the rates were consistent with those reported in the West. The prescription rate of 
self-injection epinephrine was notably low even among those who experienced 
anaphylaxis, indicating the importance of increasing the awareness of the avail-
ability of life-saving anaphylaxis management.
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objeCtives: In 2013, the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) recommendations on COPD management and prevention were updated 
to include additional therapeutic options for patients based on severity using a 
combined assessment of symptoms, degree of airflow limitation and number of 
exacerbations. The objective of the present study was to quantify the prevalence and 
incidence of COPD in the UK and estimate disease severity by 2013 GOLD categories 
A/B (low risk) and C/D (high risk). Methods: Patients with a diagnosis of COPD 
aged ≥ 40 years were identified in the population-based Clinical Practice Research 
Datalink. Point prevalence was calculated on December 31, 2013. Incidence was 
estimated using newly diagnosed patients between 2009-2013. Rates were standard-
ised using 2011 UK population age and gender. % predicted FEV1, modified British 
Medical Research Council grade and exacerbations defined by Read codes and pre-
scriptions were used to classify patients by GOLD categories. Patient characteristics 
were reported. Results: 49,286 prevalent patients were diagnosed with COPD with 
mean age of 70 years; 51% were male. Median time since diagnosis was 5 years. 
Overall prevalence was 33.0 per 1,000 people (95% CI: 32.7-33.4). Of these, 66.4% were 
classified as GOLD A/B and 33.6% as GOLD C/D. 27,224 newly diagnosed patients were 
identified with mean age of 67 years at first diagnosis; 53% were male. Incidence 
was 2.2 per 1000 person-years (95% CI: 2.1-2.2). ConClusions: A third of COPD 
patients in the UK are considered high-risk according to the 2013 GOLD categories. 
Classification of patients is key to identifying appropriate treatment options to 
reduce symptoms and the frequency of COPD exacerbations.
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objeCtives: To quantify the five-year incidence (2008-2012) and 2012 prevalence 
of COPD in The Netherlands by the Global initiative for chronic Obstructive Lung 
Disease (GOLD) 2013 combined assessment categories. Methods: Using the 
General Practitioners Database of the PHARMO Database Network, the five-year 
incidence (2008-2012) and prevalence at July 1, 2012 of COPD (ICPC code R95) by 
GOLD 2013 combined assessment categories among individuals ≥ 40 years of age 
was assessed. Based on degree of airflow limitation (using post-bronchodilator 
FEV1) and risk of exacerbations (based on medication or as recorded by the GP) 
patients were classified as low-risk COPD (FEV1 ≥ 50% and/or ≤ 1 exacerbations) or 
high-risk COPD (FEV1 < 50% and/or ≥ 2 exacerbations). Results: Using a source 
population of 813,800 individuals ≥ 40 years of age the five-year (2008-2012) inci-
dence (95% CI) of COPD among patients ≥ 40 years of age was 0.50 (0.49-0.50) per 
100 person years; this was 0.54 (0.53-0.55) among males and 0.45 (0.44-0.46) among 
females. The 2012 prevalence of COPD in a source population of 805,112 individu-
als ≥ 40 years of age was 3.7 (3.6-3.7) per 100 persons; this was 4.0 (3.9-4.1) among 
males and 3.4 (3.3-3.4) among females. Mean (± sd) age of incident and prevalent 
COPD patients was 65 ± 12 and 67 ± 12 years, respectively. The distribution of low-
risk COPD and high-risk COPD was 90% versus 10%. For patients treated by their 
GP this distribution of low-risk and high-risk COPD was similar, while patients 
treated by a specialist had a distribution of 82% versus 18%. ConClusions: This 
study describes the epidemiology of COPD in the Netherlands. Results on the 
distribution of low-risk and high-risk COPD depend on the population studied and 
the definitions used. Additional information on symptoms would allow a more 
detailed classification of patients.
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objeCtives: Mendez et al1 developed a dynamic forecasting model to predict 
the prevalence of smoking. They use initiation and prevalence rates (data from 
1965-1993) and estimate cessation rates for that period. Further, they assume the 
persistence of the cessation rates and predict future prevalence of smoking. We 
re-created the Mendez et al model in order to estimate smoking cessation rates (n) 
and updated cessation rates for 2000-2012 using newly available data on smoking 
prevalence (R). Further, smoking prevalences for the decade 2012-2024 were pre-
dicted based on a couple of alternate hypotheses of smoking initiation Methods: 
We re-created the Mendez model in Excel, including the mathematical manipu-
lations for estimates of mean rates of cessation from the years 1970-1994 and 
used the re-created Mendez model set-up and newly available data on smok-
ing prevalence (R), initiation etc. to estimate cessation rates between 2001 and 
2012. Further, we predicted smoking prevalences for 2012-2024 and explored a 
